At the news
? NEUTRALIMPACT 2/10 144 filed Nov 12, 2026 at 16:21 ET
Director Kelly Kramer filed a Form 144 notice of intent to sell 10,376 shares of Gilead Sciences common stock, with an estimated aggregate market value of approximately $1.76 million. The shares were acquired through exercise of stock options on the same day as the filing. The sale represents a routine insider transaction by a director and is not material relative to Gilead's market cap.
- Reporting person: Kelly A. Kramer, Director of Gilead Sciences
- Proposed sale of 10,376 shares of common stock
- Estimated aggregate market value: $1,761,118.48
- Shares acquired via exercise of stock options on 2026-11-12
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access